Abstract
Background A growing body of literature suggests that the triglyceride-glucose (TyG) index is linked to ischemic stroke in several ways. The usefulness of this biomarker to differentiate etiologic stroke subtypes has not been thoroughly studied. We aimed to figure out whether the TyG index differentiates cardioembolic (CE) from non-cardioembolic (NCE) strokes.
Methods A cross-sectional hospital-based study of consecutive stroke cases admitted to the University Hospital of Monastir in Tunisia from January 2018 to December 2022. The TyG index was calculated through the natural logarithm (Ln) of the product of triglyceride and glucose fasting levels. A binary logistic regression was performed to analyze the association between the TyG index and the studied stroke subtypes. We plotted the receiver operating characteristic curve (ROC curve) to determine the best cutoff point for the TyG index in differentiating between CE and NCE stroke subtypes.
Results We included 320 patients (mean age: 64.2 ±11.1 years; 65.3% males). The TyG index values were independently associated with the NCE subtype (OR=2.38; 95% CI=1.52-3.73; p<0.001) when analyzed as a continuous data variable. Logistic regression of quartile distribution showed that the probability of developing a NCE stroke increased proportionally with the TyG index quartiles. The ROC curve showed an area under the curve of 0.636 (95% CI=0.565-0.707; p<0.001) with a cutoff of 8.8 (sensitivity = 68.8%, specificity = 57%).
Conclusion High levels of the TyG index are associated with a higher prevalence of NCE stroke while low values are associated with CE strokes. Thus, the TyG index can be a useful biomarker in the differentiation between CE and NCE stroke subtypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no financial support for the research, authorship, and/or publication of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the University Hospital of Monastir approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: imen11zemni{at}gmail.com, Yasmin.saad{at}hotmail.fr, amal.abbes{at}gmail.com, ribedi{at}hotmail.fr, mariemmhiri{at}yahoo.com, belghith_asma{at}yahoo.fr, mahboubafrih{at}gmail.com
Data Availability
The data that support the findings of this study are available on request from the corresponding author, ND
Nonstandard abbreviations and acronyms
- CE
- Cardioembolic
- IR
- Insulin resistance
- Ln
- Natural logarithm
- LAA
- Large artery atheroma
- NIHSS
- National Institutes of Health Stroke Scale
- NCE
- Non cardioembolic
- SVD
- Small vessel disease
- TOAST
- Trial of ORG 10172 in Acute Stroke Treatment
- TyG
- Triglyceride-Glucose Index
